Andover, Mass.-based organ-transport system maker TransMedics raised $36 million in equity from 15 investors, the company reported.
The funding came after the company raised $6 million of a planned $22.5 million in an equity round across 9 investors last year and completed the 5th fund raise of $35.4 million with a large group of VC firms in 2010.
The latest funding round began on November 7, closing less than 10 days later on the 16th, according to SEC filings.
TransMedics develops the Organ Care System, a portable container and warm blood perfusion system designed to maintain hearts, kidneys and other organs in a functioning state while in transit from donor to recipient.
TransMedics’ Organ Care System is available for use and sale in European markets but is only approved for investigational use in the U.S.
The system for lung OCS Lung is commercially available in Europe and Australia. TransMedics plans to start the clinical trials in the U.S. soon, the company noted.